Mefenamic acid (MA), 2- [(2, 3-(dimethylphenyl) amino ] benzoic acid, is a well-known non-steroidal anti-inflammatory drug (NSAID) used for the relief of postoperative and traumatic inflammation, treatment of rheumatoid arthritis and acute respiratory tract infection. Since the free carboxylic acid moiety of MA is thought to be responsible for its increased risk of stomach ulcers and gastrointestinal disorder new compounds are designed by modifying the acid functionality of MA to ester, amide or NO releasing groups. Crystal structures of two MA derivatives,
derivatives,
prop-2-ynyl 2-(2,3-dimethylphynylamino)benzoate (2) and N'-(dihydro-2H-pyran-4(3H)-ylidene)-2-((2,3-dimethylphenyl)amino)benzohydrazide (3) have been determined using X-ray powder diffraction. The diffraction data were recorded at room temperature (293 K) using a Bruker D8 Advance diffractometer utilizing CuKα radiation ( [1] Altomare. A. et al. (2013 ) J. Appl. Cryst. 46(4), 1231 -1235 [2] Favre-Nicoli. V. and Cerny. R. (2002) J. Appl. Cryst. 35(6), 734-743. [
3] Larson. A. C. and Von Dreele. R. B. (2000) General Structure Analysis System (GSAS), Los Alamos Laboratory Report (LAUR), pp 86-748.
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